Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Inhibrx Biosciences Insider Bought Shares Worth $500,000, According to a Recent SEC Filing

Inhibrx Biosciences Insider Bought Shares Worth $500,000, According to a Recent SEC Filing

MT newswireMT newswire2026/09/23 21:01
05:01 PM EDT, 09/23/2026 (MT Newswires) -- Jon Faiz Kayyem, Director, on September 23, 2026, executed a purchase for 5,000 shares in Inhibrx Biosciences (INBX) for $500,000. Following the Form 4 filing with the SEC, Kayyem has control over a total of 1,074,046 common shares of the company, with 1,074,046 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/2007919/000136626826000011/xslF345X05/wk-form4_1790197155.xml
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion

Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.

智通财经•2026/11/10 04:31

Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output

Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.

智通财经•2026/11/10 04:12